Cytodyn Valuation

CYDY Stock  USD 0.14  0.01  6.67%   
Cytodyn seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of Cytodyn from analyzing the firm fundamentals such as Shares Outstanding of 832.97 M, return on asset of -1.48, and Shares Owned By Institutions of 0.06 % as well as examining its technical indicators and probability of bankruptcy. . In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Fairly Valued
Please note that Cytodyn's price fluctuation is out of control at this time. Calculation of the real value of Cytodyn is based on 3 months time horizon. Increasing Cytodyn's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cytodyn otc stock is determined by what a typical buyer is willing to pay for full or partial control of Cytodyn. Since Cytodyn is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cytodyn OTC Stock. However, Cytodyn's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.14 Real  0.13 Hype  0.14 Naive  0.0838
The intrinsic value of Cytodyn's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cytodyn's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Real Value
Estimating the potential upside or downside of Cytodyn helps investors to forecast how Cytodyn otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cytodyn more accurately as focusing exclusively on Cytodyn's fundamentals will not take into account other important factors:
Band Projection (param)
LowerMiddle BandUpper
LowNext ValueHigh

Cytodyn Total Value Analysis

Cytodyn is currently forecasted to have valuation of 286.7 M with market capitalization of 233.23 M, debt of 37.35 M, and cash on hands of 4.68 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cytodyn fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
286.7 M233.23 M37.35 M4.68 M

Cytodyn Investor Information

The company recorded a loss per share of 0.23. Cytodyn had not issued any dividends in recent years. CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.The quote for Cytodyn is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Cytodyn please contact the company at 360 980 8524 or go to

Cytodyn Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cytodyn has an asset utilization ratio of 0.91 percent. This suggests that the OTC Stock is making $0.009114 for each dollar of assets. An increasing asset utilization means that Cytodyn is more efficient with each dollar of assets it utilizes for everyday operations.

Cytodyn Ownership Allocation

Cytodyn retains a total of 832.97 Million outstanding shares. Cytodyn shows 7.91 percent of its outstanding shares held by insiders and 0.06 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Cytodyn Profitability Analysis

The company reported the previous year's revenue of 266 K. Net Loss for the year was (210.82 M) with loss before overhead, payroll, taxes, and interest of (73.28 M).

About Cytodyn Valuation

The otc valuation mechanism determines the current worth of Cytodyn on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Cytodyn. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Cytodyn based exclusively on its fundamental and basic technical indicators. By analyzing Cytodyn's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cytodyn's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cytodyn. We calculate exposure to Cytodyn's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cytodyn's related companies.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.

8 Steps to conduct Cytodyn's Valuation Analysis

OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Cytodyn's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cytodyn's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Cytodyn's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Cytodyn's revenue streams: Identify Cytodyn's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Cytodyn's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Cytodyn's growth potential: Evaluate Cytodyn's management, business model, and growth potential.
  • Determine Cytodyn's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cytodyn's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the otc stock being valued. We also recomment to seek professional assistance to ensure accuracy.

Cytodyn Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding719.6 M
Forward Price Earnings10.8108
Retained Earnings-766.1 M
Retained Earnings Total Equity-766.1 M

Additional Tools for Cytodyn OTC Stock Analysis

When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.